NEW DRUGS

Poster number

Title

Submitting author

City and Country

231

PRMT5 INHIBITION RESTARTS A PRO-APOPTOTIC PROGRAM AND CREATES VULNERABILITY TO COMBINATION TREATMENT WITH BCL-2 INHIBITOR VENETOCLAX IN MANTLE CELL LYMPHOMA

Fiona Brown

Columbus, OH, USA

232

CC-99282 IS A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT WITH POTENT AND BROAD ANTITUMOR ACTIVITY IN PRECLINICAL MODELS OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

Antonia Lopez-Girona

Princeton, NJ, USA

233

CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in a spectrum of NHL xenograft models

David Proia

Watertown, MA, USA

234

Glycoprotein PTGDS Acts as a Potential Target in Diffuse Large B-Cell Lymphoma by regulating MYH9-Wnt-β-catenin/STAT3 axis

Shunfeng Hu

Jinan, China

235

Clinical application of an ex-vivo platform to guide the choice of drug combinations in relapsed/refractory lymphoma; a prospective study

Anand Jeyasekharan

Singapore, Singapore

236

TG-1701, a Selective Bruton Tyrosine Kinase (BTK) Inhibitor, as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies

Chan Yoon Cheah

Perth, Australia

237

First-MIND: A Phase Ib, open-label, randomized study to assess safety of tafasitamab or tafasitamab + lenalidomide in addition to R‑CHOP in patients with newly diagnosed DLBCL

David Belada

Hradec Králové, Czech Republic

238

Clinical Activity of Loncastuximab Tesirine plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS 3 Phase 1 Results

Julien Depaus

Yvoir, Belgium

239

FINAL ANALYSIS OF A NORDIC LYMPHOMA GROUP PHASE IB/IIA TRIAL OF PIXANTRONE, ETOPOSIDE, BENDAMUSTINE AND, IN CD20-POSITIVE TUMORS, RITUXIMAB IN RELAPSED AGGRESSIVE B- OR T-CELL LYMPHOMAS

Francesco d'Amore

Aarhus, Denmark

240

Mosunetuzumab monotherapy in elderly/unfit pts with first-line diffuse large B-cell lymphoma (DLBCL): safety and efficacy remain promising with durable complete responses

Adam Olszewski

Providence, RI, USA

241

Antitumoral activity of the novel BTK inhibitor TG-1701 is associated with disruption of Ikaros signaling and improvement of anti-CD20 therapy in B-cell non-Hodgkin lymphoma

Gael Roue

Badalona, Spain

242

Promising clinical data from dose escalation in a Phase Ib/II ongoing study of mosunetuzumab with polatuzumab vedotin for relapsed/refractory B-cell non-Hodgkin’s lymphoma

Catherine Diefenbach

New York, NY, USA

243

Polatuzumab vedotin + rituximab + lenalidomide in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): primary analysis of a Phase 1b/2 trial

Catherine Diefenbach

New York, NY, USA

244

Safety and Efficacy of CD37-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-cell Lymphoma and other Non-Hodgkin’s B-cell Lymphomas – a Phase 2 Study

Moshe Levy

Dallas, TX, USA,

245

PROSPECTIVE EVALUATION OF LYMPHOMA RESPONSE TO IMMUNOMODULATORY THERAPY CRITERIA (LYRIC) IN GATA TRIAL FROM THE LYSA GROUP

Yassine Al Tabaa

Montpellier, France